Global B-cell non-Hodgkin lymphoma drugs market 2018-2022

Here are some crucial facts about the global B-cell non-Hodgkin lymphoma drugs industry

The global B-cell non-Hodgkin Lymphoma drugs market is expected to expand at a CAGR of more than 7% by 2022

B-cell non-Hodgkin lymphoma drugs industry growth is expected to accelerate over the next five years, driven by rising count of pipeline molecules for B-cell lymphoma treatment. The Americas will drive almost two-fourth of the growth of B-cell non-Hodgkin lymphoma drugs market, while EMEA and APAC are also forecasted to make substantial contributions to the incremental growth in the forecast period. The Americas held the largest market share in 2017 due to increasing prevalence of B-cell non-Hodgkin lymphoma in the region. However, the Americas and EMEA are likely to witness a decline in their market share at the end of the forecast period, while APAC looks poised to experience a higher rate of growth in the same period due to rapid technological advancements. Technavio’s B-cell non-Hodgkin lymphoma drugs industry analysis reveals promising markets around the world.

Want a bigger picture? Get a free sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Growing initiatives taken by the government is driving the demand for B-cell lymphoma treatment

Increasing funding initiatives by the government such as Cancer Breakthroughs 2020 which is likely to augment the growth of the B-cell non-Hodgkin lymphoma drugs market during the period of forecast. Also, the leading B-cell non-Hodgkin lymphoma drugs manufacturers are focusing on offering physician support programs to promote the best cure for non-Hodgkin lymphoma such as IMBRUVICA (ibrutinib), YESCARTA (Axicabtagene Ciloleucel), and Rituxan (Rituximab) which will contribute to the growth of the B-cell non-Hodgkin lymphoma drugs market in the next five years.

Get more value with Technavio’s subscription platform! Gain easy access to all Technavio’s reports, along with on-demand services.      Start your 14-day FREE trial

Biogen, F. Hoffmann-La Roche, and Merck are among the leading B-cell non-Hodgkin lymphoma drug manufacturers

Most of the leading vendors in the global B-cell non-Hodgkin lymphoma drugs market are focused on increasing the number of clinical trials for the development of B-cell non-Hodgkin lymphoma drugs. Furthermore, the approval of new therapeutic agents is likely to broaden the scope of the cure for non-Hodgkin lymphoma. The global B-cell non-Hodgkin lymphoma is predicted to experience a significant growth in the forecast period owing to increasing prevalence of non-Hodgkin lymphoma across the globe. Many international and regional vendors are vying for their share of the market, and players must differentiate themselves to gain vital traction over their peers.

This report offers a complete analysis of several companies, including:

• Biogen
• F. Hoffmann-La Roche
• Merck
• Novartis
• Spectrum Pharmaceuticals

Want to dial in on a specific region or segment? We can help! Our analysts can customize this report to meet your requirements.  Get in touch